| Sanjeda Sultana, MD | |
|
6715 Mccrimmon Pkwy Ste 300, Cary, NC 27519-1916 | |
| (919) 481-4997 | |
| (919) 388-3271 |
| Full Name | Sanjeda Sultana |
|---|---|
| Gender | Female |
| Speciality | Endocrinology |
| Experience | 13 Years |
| Location | 6715 Mccrimmon Pkwy Ste 300, Cary, North Carolina |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1558627810 | NPI | - | NPPES |
| 19W25 | Other | NC | BCBS OF NC |
| NN22770322 | Other | NC | MEDICARE |
| 1558627810 | Medicaid | NC |
| Facility Name | Location | Facility Type |
|---|---|---|
| Rex Hospital | Raleigh, NC | Hospital |
| University Of North Carolina Hospital | Chapel hill, NC | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Unc Physicians Network | 5496940546 | 709 |
News Archive
A new study has shown promising results in fighting a severe genetic disorder which can create tumours throughout the body.
Inovio Biomedical Corporation, a leader in the development of new preventive and therapeutic vaccines against cancers and infectious diseases, announced today that it has changed its corporate name to Inovio Pharmaceuticals, Inc. by filing a Certificate of Amendment to its Certificate of Incorporation with the Secretary of State of the State of Delaware on May 14, 2010. Inovio's trading symbol remains the same.
A large-scale randomized trial has recently been conducted by the World Health Organization (WHO) to evaluate the efficacy of four repurposed antiviral medicines, including Remdesivir, Hydroxychloroquine, Lopinavir, and Interferon, currently used to treat hospitalized coronavirus disease 2019 (COVID-19) patients.
The U.S. Food and Drug Administration today approved Levaquin (levofloxacin) to treat patients with plague, a rare and potentially deadly bacterial infection. The agency also approved the drug to reduce the risk of getting plague after exposure to Yersinia pestis, the bacterium that causes the disease.
› Verified 9 days ago
| Entity Name | Vidant Medical Group Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1477648731 PECOS PAC ID: 0345343893 Enrollment ID: O20070321000445 |
News Archive
A new study has shown promising results in fighting a severe genetic disorder which can create tumours throughout the body.
Inovio Biomedical Corporation, a leader in the development of new preventive and therapeutic vaccines against cancers and infectious diseases, announced today that it has changed its corporate name to Inovio Pharmaceuticals, Inc. by filing a Certificate of Amendment to its Certificate of Incorporation with the Secretary of State of the State of Delaware on May 14, 2010. Inovio's trading symbol remains the same.
A large-scale randomized trial has recently been conducted by the World Health Organization (WHO) to evaluate the efficacy of four repurposed antiviral medicines, including Remdesivir, Hydroxychloroquine, Lopinavir, and Interferon, currently used to treat hospitalized coronavirus disease 2019 (COVID-19) patients.
The U.S. Food and Drug Administration today approved Levaquin (levofloxacin) to treat patients with plague, a rare and potentially deadly bacterial infection. The agency also approved the drug to reduce the risk of getting plague after exposure to Yersinia pestis, the bacterium that causes the disease.
› Verified 9 days ago
| Entity Name | Unc Physicians Network Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1750704367 PECOS PAC ID: 5496940546 Enrollment ID: O20101115000646 |
News Archive
A new study has shown promising results in fighting a severe genetic disorder which can create tumours throughout the body.
Inovio Biomedical Corporation, a leader in the development of new preventive and therapeutic vaccines against cancers and infectious diseases, announced today that it has changed its corporate name to Inovio Pharmaceuticals, Inc. by filing a Certificate of Amendment to its Certificate of Incorporation with the Secretary of State of the State of Delaware on May 14, 2010. Inovio's trading symbol remains the same.
A large-scale randomized trial has recently been conducted by the World Health Organization (WHO) to evaluate the efficacy of four repurposed antiviral medicines, including Remdesivir, Hydroxychloroquine, Lopinavir, and Interferon, currently used to treat hospitalized coronavirus disease 2019 (COVID-19) patients.
The U.S. Food and Drug Administration today approved Levaquin (levofloxacin) to treat patients with plague, a rare and potentially deadly bacterial infection. The agency also approved the drug to reduce the risk of getting plague after exposure to Yersinia pestis, the bacterium that causes the disease.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Sanjeda Sultana, MD 5221 Paramount Pkwy Ste 220, Morrisville, NC 27560-5490 Ph: (984) 215-4110 | Sanjeda Sultana, MD 6715 Mccrimmon Pkwy Ste 300, Cary, NC 27519-1916 Ph: (919) 481-4997 |
News Archive
A new study has shown promising results in fighting a severe genetic disorder which can create tumours throughout the body.
Inovio Biomedical Corporation, a leader in the development of new preventive and therapeutic vaccines against cancers and infectious diseases, announced today that it has changed its corporate name to Inovio Pharmaceuticals, Inc. by filing a Certificate of Amendment to its Certificate of Incorporation with the Secretary of State of the State of Delaware on May 14, 2010. Inovio's trading symbol remains the same.
A large-scale randomized trial has recently been conducted by the World Health Organization (WHO) to evaluate the efficacy of four repurposed antiviral medicines, including Remdesivir, Hydroxychloroquine, Lopinavir, and Interferon, currently used to treat hospitalized coronavirus disease 2019 (COVID-19) patients.
The U.S. Food and Drug Administration today approved Levaquin (levofloxacin) to treat patients with plague, a rare and potentially deadly bacterial infection. The agency also approved the drug to reduce the risk of getting plague after exposure to Yersinia pestis, the bacterium that causes the disease.
› Verified 9 days ago
Mrs. Novlet Jarrett Davis, MD Endocrinology, Diabetes & Metabolism Medicare: Medicare Enrolled Practice Location: 875 Walnut St # 275-9, Cary, NC 27511 Phone: 919-749-6288 Fax: 919-443-1268 | |
Dr. Shilpa Bhardwaj, M.D Endocrinology, Diabetes & Metabolism Medicare: Accepting Medicare Assignments Practice Location: 6715 Mccrimmon Pkwy Ste 300, Cary, NC 27519 Phone: 919-481-4997 Fax: 919-388-3271 | |
Mohammad Saeed Anwar, MD Endocrinology, Diabetes & Metabolism Medicare: Accepting Medicare Assignments Practice Location: 210 New Edition Ct, Cary, NC 27511 Phone: 919-568-1600 Fax: 919-650-3039 | |
Dr. Scott Carter Bilbro, MD Endocrinology, Diabetes & Metabolism Medicare: Accepting Medicare Assignments Practice Location: 530 New Waverly Pl, Suite 200, Cary, NC 27511 Phone: 919-859-5955 Fax: 919-859-5659 | |
Harishchandra Mahaseth, M.D. Endocrinology, Diabetes & Metabolism Medicare: Accepting Medicare Assignments Practice Location: 105 Kilmayne Dr Ste A, Cary, NC 27511 Phone: 919-467-2253 | |
Sheila A. Shine, N.P. Endocrinology, Diabetes & Metabolism Medicare: Not Enrolled in Medicare Practice Location: 300 Ashville Ave, Ste 310, Cary, NC 27518 Phone: 919-233-8585 Fax: 919-233-8566 | |
Dr. Byron Kenneth Cole, M.D. Endocrinology, Diabetes & Metabolism Medicare: Not Enrolled in Medicare Practice Location: 401 Hickorywood Blvd., Cary, NC 27519 Phone: 919-468-9960 |